Camp A V
J Rheumatol Suppl. 1981 Jan-Feb;7:164-5.
The occurrence of thrombocytopenia and leukopenia in association with penicillamine treatment has been described, as have been isolated cases of polycythemia. Thrombocytopenia, which can occur in 8% of rheumatoid arthritis patients treated with penicillamine, is usually readily reversible on drug withdrawal or after lowering the dosage. Leukopenia and bone marrow aplasia are rare in penicillamine treatment and can occur precipitously. Frequently monitoring of all penicillamine recipients is essential to prevent such potentially fatal side effects.
已经描述了与青霉胺治疗相关的血小板减少症和白细胞减少症的发生情况，也有红细胞增多症的个别病例报道。血小板减少症可发生在8%接受青霉胺治疗的类风湿关节炎患者中，通常在停药或降低剂量后很容易逆转。白细胞减少症和骨髓再生障碍在青霉胺治疗中很少见，且可能突然发生。对所有接受青霉胺治疗的患者进行频繁监测对于预防此类潜在致命副作用至关重要。
